In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?
Menée à partir des données de l'enquête rétrospective "Adelphi Real World", cette étude examine les raisons des médecins justifiant, malgré les recommandations, la non intensification des traitements chez les patients atteints d'un cancer métastatique de la prostate (617 cas ; âge moyen : 68,6 ans)
Elsewhere in JAMA Network Open, Agarwal et al report the findings of an Adelphi Real World retrospective survey to evaluate practice patterns of 107 US physicians treating patients with metastatic castration-sensitive prostate cancer (mCSPC) between July 2018 and January 2022. The survey comprised urologists (n = 42) and medical oncologists (n = 65), reporting community (n = 68) and academic (n = 39) affiliations. The authors found that less than one-third of patients received first-line treatment intensification (TI) with an androgen receptor pathway inhibitor (ARPI) and/or docetaxel. An additional 27% of patients received delayed TI in subsequent therapy for mCSPC. These results confirm poor utilization of guideline-recommended intensification therapy for US patients with mCSPC.